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Integrase strand transfer inhibitors (INSTIs) such as
raltegravir have become a key component of antiviral
therapy. We have recently described the development of
a novel class of integration inhibitors, 2-(quinolin-3-yl)
acetic acid derivatives, that potently block HIV replica-
tion (Christ et al. Nature Chemical Biology 2010).
Unlike clinically approved INSTIs, these compounds do
not bind to the catalytic site of HIV integrase (IN). As
allosteric inhibitors they bind to the LEDGF/ p75 bind-
ing pocket in integrase, hence the class name LEDGINs.
This prevents the interaction with LEDGF/p75, a mole-
cular tether of HIV IN, and inhibits the catalytic activ-
ities of IN. Detailed mechanism of action studies reveal
that the allosteric mode of inhibition is due to the stabi-
lization of the IN dimer. Recently, we demonstrated that
LEDGINs also inhibit late stage HIV replication by stabi-
lization of IN multimers. Evidence suggests that LEDGF/
p75 may play a role in this process. Lack of cross-resis-
tance with available IN inhibitors and potency due to the
multistep inhibition, support the further clinical develop-
ment of LEDGINs.
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